FDAnews
www.fdanews.com/articles/101062-nastech-pharmaceutical-begins-restructuring

Nastech Pharmaceutical Begins Restructuring

November 14, 2007

Nastech Pharmaceutical will concentrate on Phase II clinical and partnered programs as part of its corporate restructuring efforts.

The company has several Phase II programs planned or under way, including PYY3-36 nasal spray for obesity, insulin nasal spray for Type 2 diabetes and PTH1-34 nasal spray for osteoporosis.

Nastech also will move forward with establishing its subsidiary MDRNA as an independent company, it said.